#160536

Anti-Cadherin 6 [2B6-D8]

Cat. #160536

Anti-Cadherin 6 [2B6-D8]

Cat. #: 160536

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Cadherin-6

Class: Monoclonal

Application: IHC

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jack A Schalken

Institute: Radboud University Medical Center (UMC)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Cadherin 6 [2B6-D8]
  • Alternate name: Cadherin 6, CDH6
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Host: Mouse
  • Application: IHC
  • Description: From Shimazui et al Clin Cancer Res. 1998 Oct;4(10):2419-24. "In many carcinomas, E-cadherin is considered to be a prognostic marker for patient survivals, and its decreased expression is associated with metastatic disease. Among renal cell carcinomas (RCCs), however, only 20% of tumors express E-cadherin, whereas a much higher percentage express other cadherins, e.g., N-cadherin and cadherin-6. Among these cadherins expressed in RCCs, cadherin-6 has been identified as a major cadherin in the renal proximal tubules and in the tumors themselves." The inventors of this reagent found that " These results suggest that cadherin-6 is a major cadherin playing an essential role in cell-cell adhesion in E-cadherin-absent RCC."
  • Immunogen: glutathione S-transferase (GST) fusion extracellular domain of human cadherin-6a
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Cadherin-6
  • Target background: From Shimazui et al Clin Cancer Res. 1998 Oct;4(10):2419-24. "In many carcinomas, E-cadherin is considered to be a prognostic marker for patient survivals, and its decreased expression is associated with metastatic disease. Among renal cell carcinomas (RCCs), however, only 20% of tumors express E-cadherin, whereas a much higher percentage express other cadherins, e.g., N-cadherin and cadherin-6. Among these cadherins expressed in RCCs, cadherin-6 has been identified as a major cadherin in the renal proximal tubules and in the tumors themselves." The inventors of this reagent found that " These results suggest that cadherin-6 is a major cadherin playing an essential role in cell-cell adhesion in E-cadherin-absent RCC."

Applications

  • Application: IHC

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C

References

  • Shimazui et al. 1998. Clin Cancer Res. 4(10):2419-24. PMID: 9796973.